Mohamad Bitar, MD
Pulmonary Disease · Grand Forks, NDNPI 1699202440
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,500 of the $7,562 with a category attached, or 72.7%. Intuitive Surgical accounts for 96.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $7,040 and has fallen 94.6% since, to $378 in 2025.
Across 19 payments — averaging $398.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Pulmonx Corporation$102
- Angiodynamics, Inc.$60
- Sanofi$59
- Novo Nordisk$37
- Pfizer$32
- plus $16 from 1 others
What the payments were for
- Travel & lodging$1,70022%
- Food & beverage$3625%
- Education$5,50073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $7,256 |
| Pulmonx Corporation | 1 | $102 |
| Angiodynamics, Inc. | 1 | $60 |
| Sanofi | 2 | $59 |
| Novo Nordisk | 3 | $37 |
| Pfizer | 2 | $32 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,562 in reported general payments places this provider in the 75th percentile of 31 pulmonary disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 38 | $153,223 |
| OfevNintedanib Esylate | 11 | $140,557 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $54,377 |
| Spiriva RespimatTiotropium Bromide | 61 | $36,785 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $25,396 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $22,727 |
| Incruse ElliptaUmeclidinium Bromide | 56 | $19,677 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $18,871 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 58 | $12,802 |
| Arnuity ElliptaFluticasone Furoate | 38 | $11,987 |
| Spiriva HandihalerTiotropium Bromide | 18 | $9,105 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,102 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $5,979 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,804 |
| DuleraMometasone/Formoterol | 13 | $4,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $16 | $200,068112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 31 pulmonary disease providers in North Dakota.
Other pulmonary disease in Grand Forks
- Antranik MangardichGrand Forks$8K
- Naresh VeerabattiniGrand Forks$3K
- Umamaheswara MudireddyGrand Forks$2K
- Mokhtarodin ShakibaniGrand Forks$96
- Seema KhoslaFargo$43K
- Alfredo IardinoBismarck$26K
- Haven MalishBismarck$16K
- Venkatkiran KanchustambhamFargo$14K
- Bhaja ShresthaBismarck$10K
- Michael TalalaevFargo$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.